Skip Navigation Links.
American Journal of Clinical Medicine Research. 2014, 2(1), 32-35
DOI: 10.12691/AJCMR-2-1-8
Review Article

Donor Selection in Allogeneic Stem Cell Transplantation

Mehmet Ali ERKURT1, Ilhami BERBER1, , Irfan KUKU1, Emin KAYA1 and Ilknur NIZAM1

1Department of Hematology, Faculty of Medicine, Inonu University, Malatya, Turkey

Pub. Date: February 09, 2014
Full Text PDF

Cite this paper

Mehmet Ali ERKURT, Ilhami BERBER, Irfan KUKU, Emin KAYA and Ilknur NIZAM. Donor Selection in Allogeneic Stem Cell Transplantation. American Journal of Clinical Medicine Research. 2014; 2(1):32-35. doi: 10.12691/AJCMR-2-1-8

Abstract

Allogeneic hematopoietic stem cell transplant is safe and curative treatment modality for many hematologic diseases. Expanding alternative donor options such as haploidentical hematopoietic stem cell transplantation and umbilical cord blood, taken together with enhanced outcomes of matched unrelated donors, has resulted in a advisable donor for most patients with an hematopoietic stem cell transplantation indication. This review article provides improved patient selection, offers hope for decreasing relapse and improving outcomes for in patients applied allogeneic hematopoietic stem cell transplant.

Keywords

allogeneic, donor selection, stem cell transplantation

Copyright

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]  Gupta V., Tallman M.S., He W., Logan B.R., Copelan E., Gale R.P., Khoury H.J., Klumpp T., Koreth J., Lazarus H.M., Marks D.I., Martino R., Rizzieri D.A., Rowe J.M., Sabloff M., Waller E.K., DiPersio J.F., Bunjes D.W., Weisdorf D.J., “Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis, “Blood, 116 (11).1839-1848. Sep. 2010.
 
[2]  Horton R., Wilming L., Rand V., Lovering R.C., Bruford E.A., Khodiyar V.K., Lush M.J., Povey S., Talbot C.C Jr., Wright M.W., Wain H.M., Trowsdale J., Ziegler A., Beck S., “Gene map of the extended human MHC, “ Nat Rev Genet, 5(12).889-899. Dec. 2004.
 
[3]  Anasetti C., “What are the most important donor and recipient factors affecting the outcome of related and unrelated allogeneic transplantation?, “Best Pract Res Clin Haematol, 21(4).691-697. Dec. 2008.
 
[4]  Busch R., Mellins E.D., “Developing and shedding inhibitions: how MHC class II molecules reach maturity, “Curr Opin Immunol, 8 (1).51-58. Feb. 1996.
 
[5]  Holcomb C.L., Höglund B., Anderson MW., Blake LA., Böhme I., Egholm M., Ferriola D., Gabriel C., Gelber S.E., Goodridge D., Hawbecker S., Klein R., Ladner M., Lind C., Monos D., Pando M.J., Pröll J., Sayer D.C., Schmitz-Agheguian G., Simen B.B., Thiele B., Trachtenberg E.A., Tyan D.B., Wassmuth R., White S., Erlich H.A., “A multi-site study using high-resolution HLA genotyping by next generation sequencing, “ Tissue Antigens, 77(3).206-217. Mar. 201.
 
[6]  Petersdorf E.W., Gooley T.A., Anasetti C., Martin P.J., Smith A.G., Mickelson E.M., Woolfrey A.E., Hansen J.A., “Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient, “ Blood, 92(10). 3515-3520. Nov. 1998.
 
[7]  Park M., Seo J., “Role of HLA in Hematopoietic Stem Cell Transplantation, “Bone Marrow Res, 2012; 2012:680841.
 
[8]  Lown R.N., Shaw B.E., “Beating the odds: factors implicated in the speed and availability of unrelated haematopoietic cell donor provision, “ Bone Marrow Transplant, 48 (2). 210-219. Feb. 2013.
 
[9]  Kögler G., Somville T., Göbel U., Hakenberg P., Knipper A., Fischer J., Adams O., Krempe C., McKenzie C., Rüttgers H., Meier W., Bellmann O., Streng H., Ring A., Rosseck U., Rocha V., Wernet P., “ Haematopoietic transplant potential of unrelated and related cord blood: the first six years of the UROCORD/NETCORD Bank Germany, “Klin Padiatr, 211(4).224-232. Jul-Aug .1999.
 
[10]  Sullivan M.J., “Banking on cord blood stem cells, “Nat Rev Cancer, 8(7).555-563. Jul. 2008.
 
[11]  Armitage J.O., “Bone Marrow Transplantation, “N Engl J Med, 330(12).827-838. Mar. 1994
 
[12]  Lee S.J., Klein J., Haagenson M., Baxter-Lowe L.A, Confer D.L, Eapen M., Fernandez-Vina M., Flomenberg N., Horowitz M., Hurley C.K., Noreen H., Oudshoorn M., Petersdorf E., Setterholm M., Spellman S., Weisdorf D., Williams T.M., Anasetti C., “High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation, “ Blood, 110 (13). 4576-4583. Dec. 2007.
 
[13]  Loiseau P., Busson M., Balere M.L., Dormoy A., Bignon J.D., Gagne K., Gebuhrer L., Dubois V., Jollet I., Bois M., Perrier P., Masson D., Moine A., Absi L., Reviron D., Lepage V., Tamouza R., Toubert A., Marry E., Chir Z., Jouet J.P., Blaise D., Charron D., Raffoux C., “HLA Association with hematopoietic stem cell transplantation outcome: the number of mismatches at HLA-A, -B, -C, -DRB1, or -DQB1 is strongly associated with overall survival, “ Biol Blood Marrow Transplant, 13 (8). 965-974. Aug. 2007.
 
[14]  Fürst D., Müller C., Vucinic V., Bunjes D., Herr W., Gramatzki M., Schwerdtfeger R., Arnold R., Einsele H., Wulf G., Pfreundschuh M., Glass B., Schrezenmeier H., Schwarz K., Mytilineos J., “ High-resolution HLA matching in hematopoietic stem cell transplantation: a retrospective collaborative analysis, “Blood, 122 (18).3220-3229. Oct. 2013.
 
[15]  Frassoni F., Labopin M., Powles R., Mary J.Y., Arcese W., Bacigalupo A., Bunjes D., Gluckman E., Ruutu T., Schaefer U.W., Sierra J., Vernant J.P., Willemze R., de Witte T., Gorin N.C., “Effect of centre on outcome of bone-marrow transplantation for acute myeloid leukaemia. Acute Leukaemia Working Party of the European Group for Blood and Marrow Transplantation, “Lancet, 355(9213).1393-1398. April. 2000.
 
[16]  Woolfrey A., Klein J.P., Haagenson M., Spellman S., Petersdorf E., Oudshoorn M., Gajewski J., Hale G.A., Horan J., Battiwalla M., Marino S.R., Setterholm M., Ringden O., Hurley C., Flomenberg N., Anasetti C., Fernandez-Vina M., Lee S.J., “ HLA-C antigen mismatch is associated with worse outcome in unrelated donor peripheral blood stem cell transplantation. “Biol Blood Marrow Transplant, 17(6). 885-892. June 2011.
 
[17]  Spellman S., Bray R., Rosen-Bronson S., Haagenson M., Klein J., Flesch S., Vierra-Green C., Anasetti C., “The detection of donor-directed, HLA-specific alloantibodies in recipients of unrelated hematopoietic cell transplantation is predictive of graft failure, “Blood, 115(13). 2704-2708. April. 2010.
 
[18]  Liang R., “How I treat and monitor viral hepatitis B infection in patients receiving intensive immunosuppressive therapies or undergoing hematopoietic stem cell transplantation, “ Blood, 113(14). 3147-3153. Apr. 2009.
 
[19]  Tomás J.F., Rodriguez-Iñigo E., Bartolomé J., Alegre A., Fernández-Rañada J.M., Carreño V., “Transplantation of allogeneic CD34-selected peripheral stem cells does not prevent transmission of hepatitis C virus from an infected donor, “ Bone Marrow Transplant, 24(1).109-112. Jul.1999.
 
[20]  Lau G.K., Lie A.K., Kwong Y.L., Lee C.K., Hou J., Lau Y.L., Lim W.L., Liang R.. “A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation, “Blood, 96(2).452-458. Jul.2000.
 
[21]  Choi S.M., Lee D.G., Choi J.H., Yoo J.H., Kim Y.J., Park S.H., Min C.K., Lee S., Kim H.J., Kim D.W., Lee J.W., Min W.S., Shin W.S., Kim C.C., “Risk-adapted preemptive therapy for cytomegalovirus disease after allogeneic stem cell transplantation: a single-center experience in Korea, “ Int J Hematol, 83(3).277-278. Apr.2006
 
[22]  Parody R., Martino R., Rovira M., Vazquez L., Vázquez M.J., de la Cámara R., Blazquez C., Fernández-Avilés F., Carreras E., Salavert M., Jarque I., Martín C., Martínez F., López J., Torres A., Sierra J., Sanz G.F.; Infectious/Non-infectious Complications Subcommittee of the Grupo Español de Trasplante Hematopoyético (GETH) “ Severe infections after unrelated donor allogeneic hematopoietic stem cell transplantation in adults: comparison of cord blood transplantation with peripheral blood and bone marrow transplantation, “Blood Marrow Transplant, 12(7).734-748. Jul.2006.
 
[23]  Schmidt-Hieber M., Labopin M., Beelen D., Volin L., Ehninger G., Finke J., Socié G., Schwerdtfeger R., Kröger N., Ganser A., Niederwieser D., Polge E., Blau I.W., Mohty M., “CMV serostatus still has an important prognostic impact in de novo acute leukemia patients after allogeneic stem cell transplantation: a report from the Acute Leukemia Working Party of EBMT, “Blood, 122(19).3359-3364. Nov. 2013. Epub 2013 Sep 13.
 
[24]  Kanda J., Ichinohe T., Matsuo K., Benjamin R.J., Klumpp T.R., Rozman P., Blumberg N., Mehta J., Sohn S.K., Uchiyama T.,“ Impact of ABO mismatching on the outcomes of allogeneic related and unrelated blood and marrow stem cell transplantations for hematologic malignancies, “IPD-based meta-analysis of cohort studies, 49(4).624-635. Apr. 2009.
 
[25]  Erker C.G., Steins M.B., Fischer R.J., Kienast J., Berdel W.E., Sibrowski W., Cassens U., “The influence of blood group differences in allogeneic hematopoietic peripheral blood progenitor cell transplantation, “Transfusion, 45(8).1382-1290. Aug.2005
 
[26]  Wirk B., Klumpp T.R., Ulicny J., Herman J.H., Gajewski J.L., Martin M.E., Emmons RV, Mangan KF. “Lack of effect of donor-recipient Rh mismatch on outcomes after allogeneic hematopoietic stem cell transplantation, “Transfusion, 48(1).163-1688. Jan. 2008. Epub 2007 Sep 27.
 
[27]  Kollman C., Howe C.W., Anasetti C., Antin J.H., Davies S.M., Filipovich A.H., Hegland J., Kamani N., Kernan N.A., King R., Ratanatharathorn V., Weisdorf D., Confer D.L., “Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age, “ Blood, 98(7).2043-2051. Oct.2001.
 
[28]  Loren A.W., Bunin G.R., Boudreau C., Champlin R.E., Cnaan A., Horowitz M.M., Loberiza F.R., Porter D.L.. “Impact of donor and recipient sex and parity on outcomes of HLA-identical sibling allogeneic hematopoietic stem cell transplantation, “ Biol Blood Marrow Transplant, 12(7). 758-69. Jul. 2006.
 
[29]  Nannya Y., Kataoka K., Hangaishi A., Imai Y., Takahashi T., Kurokawa M., “ The negative impact of female donor/male recipient combination in allogeneic hematopoietic stem cell transplantation depends on disease risk, “Transpl Int, 24(5).469-476. May. 2011.